SPRINGWORKS THERAPEUTICS INC (SWTX) Fundamental Analysis & Valuation

NASDAQ:SWTX • US85205L1070

Current stock price

46.99 USD
+0.01 (+0.02%)
At close:
46.98 USD
-0.01 (-0.02%)
After Hours:

This SWTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. SWTX Profitability Analysis

1.1 Basic Checks

  • SWTX had negative earnings in the past year.
  • In the past year SWTX has reported a negative cash flow from operations.
  • In the past 5 years SWTX always reported negative net income.
  • SWTX had a negative operating cash flow in each of the past 5 years.
SWTX Yearly Net Income VS EBIT VS OCF VS FCFSWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -50.25%, SWTX is in line with its industry, outperforming 49.64% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -60.84%, SWTX is in the better half of the industry, outperforming 60.14% of the companies in the same industry.
Industry RankSector Rank
ROA -50.25%
ROE -60.84%
ROIC N/A
ROA(3y)-44.26%
ROA(5y)-35.82%
ROE(3y)-51.76%
ROE(5y)-40.92%
ROIC(3y)N/A
ROIC(5y)N/A
SWTX Yearly ROA, ROE, ROICSWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

  • SWTX's Gross Margin of 93.23% is amongst the best of the industry. SWTX outperforms 94.31% of its industry peers.
  • The Profit Margin and Operating Margin are not available for SWTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SWTX Yearly Profit, Operating, Gross MarginsSWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. SWTX Health Analysis

2.1 Basic Checks

  • SWTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SWTX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SWTX has been increased compared to 5 years ago.
  • SWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SWTX Yearly Shares OutstandingSWTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SWTX Yearly Total Debt VS Total AssetsSWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 20.07 indicates that SWTX is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 20.07, SWTX belongs to the best of the industry, outperforming 93.59% of the companies in the same industry.
  • SWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.07
ROIC/WACCN/A
WACC9.79%
SWTX Yearly LT Debt VS Equity VS FCFSWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 4.33 indicates that SWTX has no problem at all paying its short term obligations.
  • SWTX has a Current ratio (4.33) which is in line with its industry peers.
  • A Quick Ratio of 4.18 indicates that SWTX has no problem at all paying its short term obligations.
  • SWTX has a Quick ratio (4.18) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.33
Quick Ratio 4.18
SWTX Yearly Current Assets VS Current LiabilitesSWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. SWTX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 33.79% over the past year.
  • Looking at the last year, SWTX shows a very strong growth in Revenue. The Revenue has grown by 730.42%.
EPS 1Y (TTM)33.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.93%
Revenue 1Y (TTM)730.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%133.68%

3.2 Future

  • SWTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.73% yearly.
  • The Revenue is expected to grow by 40.44% on average over the next years. This is a very strong growth
EPS Next Y19.4%
EPS Next 2Y25.17%
EPS Next 3Y32.89%
EPS Next 5Y19.73%
Revenue Next Year71.54%
Revenue Next 2Y73.57%
Revenue Next 3Y60.55%
Revenue Next 5Y40.44%

3.3 Evolution

SWTX Yearly Revenue VS EstimatesSWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
SWTX Yearly EPS VS EstimatesSWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. SWTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SWTX. In the last year negative earnings were reported.
  • Also next year SWTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SWTX Price Earnings VS Forward Price EarningsSWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SWTX Per share dataSWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • SWTX's earnings are expected to grow with 32.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.17%
EPS Next 3Y32.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SWTX Dividend Analysis

5.1 Amount

  • No dividends for SWTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SWTX Fundamentals: All Metrics, Ratios and Statistics

SPRINGWORKS THERAPEUTICS INC

NASDAQ:SWTX (6/30/2025, 8:00:01 PM)

After market: 46.98 -0.01 (-0.02%)

46.99

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09
Earnings (Next)08-05
Inst Owners85.23%
Inst Owner Change-13.81%
Ins Owners1.38%
Ins Owner Change0%
Market Cap3.54B
Revenue(TTM)219.67M
Net Income(TTM)-253.93M
Analysts50.91
Price Target53.33 (13.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-40.05%
Min EPS beat(2)-44.63%
Max EPS beat(2)-35.47%
EPS beat(4)2
Avg EPS beat(4)-5.34%
Min EPS beat(4)-44.63%
Max EPS beat(4)52.52%
EPS beat(8)5
Avg EPS beat(8)-3.18%
EPS beat(12)7
Avg EPS beat(12)-2.43%
EPS beat(16)7
Avg EPS beat(16)-7.99%
Revenue beat(2)1
Avg Revenue beat(2)-12.64%
Min Revenue beat(2)-27.36%
Max Revenue beat(2)2.07%
Revenue beat(4)2
Avg Revenue beat(4)9.03%
Min Revenue beat(4)-27.36%
Max Revenue beat(4)70.52%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-28.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.25%
EPS NY rev (1m)-7.21%
EPS NY rev (3m)-15.2%
Revenue NQ rev (1m)-3.51%
Revenue NQ rev (3m)-4.74%
Revenue NY rev (1m)-2.75%
Revenue NY rev (3m)-6.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.11
P/FCF N/A
P/OCF N/A
P/B 8.48
P/tB 8.48
EV/EBITDA N/A
EPS(TTM)-3.41
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS2.92
BVpS5.54
TBVpS5.54
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -50.25%
ROE -60.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.23%
FCFM N/A
ROA(3y)-44.26%
ROA(5y)-35.82%
ROE(3y)-51.76%
ROE(5y)-40.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 524.84%
Cap/Sales 9.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.33
Quick Ratio 4.18
Altman-Z 20.07
F-Score6
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)788.2%
Cap/Depr(5y)591.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.93%
EPS Next Y19.4%
EPS Next 2Y25.17%
EPS Next 3Y32.89%
EPS Next 5Y19.73%
Revenue 1Y (TTM)730.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%133.68%
Revenue Next Year71.54%
Revenue Next 2Y73.57%
Revenue Next 3Y60.55%
Revenue Next 5Y40.44%
EBIT growth 1Y26.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.3%
OCF growth 3YN/A
OCF growth 5YN/A

SPRINGWORKS THERAPEUTICS INC / SWTX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SPRINGWORKS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SWTX.


What is the valuation status of SPRINGWORKS THERAPEUTICS INC (SWTX) stock?

ChartMill assigns a valuation rating of 1 / 10 to SPRINGWORKS THERAPEUTICS INC (SWTX). This can be considered as Overvalued.


What is the profitability of SWTX stock?

SPRINGWORKS THERAPEUTICS INC (SWTX) has a profitability rating of 1 / 10.


How financially healthy is SPRINGWORKS THERAPEUTICS INC?

The financial health rating of SPRINGWORKS THERAPEUTICS INC (SWTX) is 7 / 10.